Breast Surgery Specialist Stephanie Valente, DO, discusses the diagnosis and treatment of Paget’s disease, a rare form of ductal carcinoma in situ that may look like eczema or psoriasis of the nipple and areola.
Recent study analyzes the role of surgical margins for mastectomy after DCIS.
Biosignature improves on ability to understand recurrence risk of disease in patients with ductal carcinoma in situ.
New study findings help clinicians understand which patients with DCIS are most appropriate for radiation therapy.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A new study examines the use of a seven-gene predictive DCIS biosignature to assess when endocrine therapy may benefit patients following breast-conserving surgery.
Results from a multi-institutional study led by a Cleveland Clinic researcher, DCSionRT®, a biosignature based on multiple biomarkers, may hold the key to solving the treatment of ductal carcinoma in situ (DCIS).
Recent breast cancer mortality data have prompted suggestions that a more conservative approach to treating ductal carcinoma in situ may be appropriate in many cases. Cleveland Clinic Cancer Center radiation oncologist Chirag Shah, MD, and colleagues provide perspective on what’s known and what additional research is needed.